These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 18192970)
1. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Simonavicius N; Robertson D; Bax DA; Jones C; Huijbers IJ; Isacke CM Mod Pathol; 2008 Mar; 21(3):308-15. PubMed ID: 18192970 [TBL] [Abstract][Full Text] [Related]
2. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Rybinski K; Imtiyaz HZ; Mittica B; Drozdowski B; Fulmer J; Furuuchi K; Fernando S; Henry M; Chao Q; Kline B; Albone E; Wustner J; Lin J; Nicolaides NC; Grasso L; Zhou Y Oncotarget; 2015 Sep; 6(28):25429-40. PubMed ID: 26327620 [TBL] [Abstract][Full Text] [Related]
3. Endosialin: molecular and functional links to tumor angiogenesis. Kontsekova S; Polcicova K; Takacova M; Pastorekova S Neoplasma; 2016; 63(2):183-92. PubMed ID: 26774137 [TBL] [Abstract][Full Text] [Related]
4. Characterization of TEM1/endosialin in human and murine brain tumors. Carson-Walter EB; Winans BN; Whiteman MC; Liu Y; Jarvela S; Haapasalo H; Tyler BM; Huso DL; Johnson MD; Walter KA BMC Cancer; 2009 Nov; 9():417. PubMed ID: 19948061 [TBL] [Abstract][Full Text] [Related]
5. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Bagley RG; Honma N; Weber W; Boutin P; Rouleau C; Shankara S; Kataoka S; Ishida I; Roberts BL; Teicher BA Microvasc Res; 2008 Nov; 76(3):180-8. PubMed ID: 18761022 [TBL] [Abstract][Full Text] [Related]
6. Novel monoclonal antibodies specific for CTLD-SSC and sialomucin domains of endosialin, a mural cell marker of tumor vasculature. Kontseková S; Ohradanova Repic A; Polčicová K; Tuomaala P; Pastorek J; Pastoreková S; Parkkila S; Baráthová M Int J Oncol; 2012 Oct; 41(4):1365-72. PubMed ID: 22824847 [TBL] [Abstract][Full Text] [Related]
7. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches. Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138 [TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature and glioma stem cells: Contributions to glioma progression. Jhaveri N; Chen TC; Hofman FM Cancer Lett; 2016 Oct; 380(2):545-551. PubMed ID: 25527451 [TBL] [Abstract][Full Text] [Related]
9. Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. Svensson A; Özen I; Genové G; Paul G; Bengzon J PLoS One; 2015; 10(4):e0123553. PubMed ID: 25875288 [TBL] [Abstract][Full Text] [Related]
10. Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma. Huizer K; Zhu C; Chirifi I; Krist B; Zorgman D; van der Weiden M; van den Bosch TPP; Dumas J; Cheng C; Kros JM; Mustafa DA J Neuropathol Exp Neurol; 2020 Aug; 79(8):863-872. PubMed ID: 32647861 [TBL] [Abstract][Full Text] [Related]
11. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Christian S; Winkler R; Helfrich I; Boos AM; Besemfelder E; Schadendorf D; Augustin HG Am J Pathol; 2008 Feb; 172(2):486-94. PubMed ID: 18187565 [TBL] [Abstract][Full Text] [Related]
12. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670 [TBL] [Abstract][Full Text] [Related]
13. Pericytes promote selective vessel regression to regulate vascular patterning. Simonavicius N; Ashenden M; van Weverwijk A; Lax S; Huso DL; Buckley CD; Huijbers IJ; Yarwood H; Isacke CM Blood; 2012 Aug; 120(7):1516-27. PubMed ID: 22740442 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360 [TBL] [Abstract][Full Text] [Related]